Method to inhibit cancer targeting CD24
Inventors
Shin, Young Kee • Choi, Yoon-La • Park, Young Woo • Lee, Seung Hyun • Song, Kyoung
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-8425906-B2
Publication Date
2013-04-23
Expiration Date
Abstract
The present invention relates to a method to inhibit cancer by targeting CD24, more precisely a method to inhibit cancer by using CD24 expressed in most cancer cells as a target of an antibody therapeutic agent or by inhibiting the interaction between CD24 and P-selectin. CD24 is over-expressed in most cancer cells and CD24 accumulated in cytoplasm accelerates metastasis. Therefore, the method to inhibit cancer of the invention by targeting CD24 can be effectively used for the treatment of cancer by inhibiting the progress of various cancers over-expressing CD24.
Core Innovation
The described invention relates to inhibiting cancer by targeting CD24, which is overexpressed in many cancer types and can accelerate metastasis when present in cytoplasm. The invention addresses cancer growth and metastasis associated with CD24 overexpression by providing CD24-targeting therapeutic approaches directed to cancer cells that overexpress CD24.
The invention proposes administering an anti-CD24 antibody as an antibody therapeutic agent to a subject having cancer overexpressing CD24. In that approach, the anti-CD24 antibody is configured to inhibit the cancer and is associated with complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) as described in the summary.
The invention further includes co-administration concepts in which an anti-CD24 antibody is administered together with another anticancer agent, including chemotherapeutic, radiotherapeutic, or immunotherapeutic agents, to inhibit CD24-overexpressing cancer. Additional disclosed approaches include blocking CD24 interaction with P-selectin (CD62P) as part of the CD24-targeting strategy, with the document presenting reported inhibition of tumor growth in a xenograft model and reductions in tumor size relative to control.
Claims Coverage
The independent claims covered by the provided list are clm-00001 and clm-00005. The inventive features focus on administering an anti-CD24 antibody to inhibit CD24-overexpressing cancer, optionally co-administering another anticancer agent, and dependent refinements specifying antibody recognition features and cytotoxic mechanisms (CDC and ADCC) as well as the cancer indications.
Administering an anti-CD24 antibody to inhibit CD24-overexpressing cancer
Administering a therapeutically effective amount of an anti-CD24 antibody to a subject having cancer overexpressing CD24.
Co-administering an anti-CD24 antibody with another anticancer agent
Co-administering a therapeutically effective amount of an anti-CD24 antibody and another anticancer agent to a subject having cancer overexpressing CD24.
Overall, the claim coverage centers on anti-CD24 antibody administration, alone or with a second anticancer agent, to inhibit cancer that overexpresses CD24, with dependent refinements specifying antibody recognition, functional cytotoxic mechanisms, and enumerated cancer indications.
Stated Advantages
Inhibits cancer overexpressing CD24 by targeting CD24 with an anti-CD24 antibody.
Associated with complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) as described in the summary.
Reduces tumor size in an in vivo xenograft model relative to control, as described in the summary.
Documented Applications
Treatment of cancer overexpressing CD24, including ovarian cancer, breast cancer, small cell lung cancer, prostatic cancer, pancreatic cancer, rectal cancer, bladder cancer, liver cancer, small intestine cancer, large intestine cancer, cervical cancer, and cholangiocarcinoma, as described in the summary and dependent claims.
Combination therapy use case in which an anti-CD24 antibody is co-administered with chemotherapeutic, radiotherapeutic, or immunotherapeutic agents to inhibit the CD24-overexpressing cancer, as described in the summary and independent claim refinements.
Radiotherapeutic adjunct concepts are described, including use of a radiotherapeutic agent with nuclides selected from a specified set, as reflected by dependent claim refinements.
Interested in licensing this patent?